ProShare Advisors LLC Invests $142,000 in Capricor Therapeutics Inc (NASDAQ:CAPR)

ProShare Advisors LLC acquired a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 10,317 shares of the biotechnology company’s stock, valued at approximately $142,000.

A number of other large investors have also made changes to their positions in CAPR. Charles Schwab Investment Management Inc. lifted its holdings in shares of Capricor Therapeutics by 51.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock worth $1,536,000 after acquiring an additional 37,868 shares during the period. Swiss National Bank acquired a new position in Capricor Therapeutics during the fourth quarter worth approximately $930,000. Alliancebernstein L.P. purchased a new position in Capricor Therapeutics during the fourth quarter worth approximately $183,000. The Manufacturers Life Insurance Company raised its stake in Capricor Therapeutics by 22.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 2,361 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Capricor Therapeutics by 37.8% during the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock worth $12,139,000 after buying an additional 241,279 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Price Performance

Shares of CAPR opened at $10.21 on Tuesday. Capricor Therapeutics Inc has a 12 month low of $3.52 and a 12 month high of $23.40. The stock’s 50-day moving average is $10.15 and its two-hundred day moving average is $13.05. The stock has a market cap of $466.36 million, a PE ratio of -9.63 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The company had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.16 million. During the same period last year, the firm posted ($0.31) earnings per share. On average, research analysts anticipate that Capricor Therapeutics Inc will post -1.21 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Wall Street Zen cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Roth Capital started coverage on Capricor Therapeutics in a report on Tuesday, May 20th. They set a “buy” rating and a $31.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Monday, March 17th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $35.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.